Compare
Cytek Biosciences, Inc. vs Quanterix Corp vs 10x Genomics, Inc. vs 908 Devices Inc.
| Latest fiscal year | Cytek Biosciences, Inc. CTKB | Quanterix Corp QTRX | 10x Genomics, Inc. TXG | 908 Devices Inc. MASS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $201.49M | $138.90M | $642.82M | $56.20M |
| Revenue growth (YoY) | +0.5% | +1.1% | +5.2% | +17.7% |
| Gross margin | 51.8% | 46.8% | 69.1% | 50.6% |
| Operating margin | -20.0% | -90.4% | -9.5% | -70.1% |
| Net margin | -33.0% | -77.1% | -6.8% | 34.7% |
| Net income | -$66.54M | -$107.15M | -$43.54M | $19.49M |
| EPS (Diluted) | n/a | -$2.51 | -$0.35 | $0.54 |
| Operating cash flow | -$4.69M | -$77.24M | $136.05M | -$23.69M |
| Free cash flow | -$8.77M | -$79.85M | $130.12M | -$24.64M |
| Cash & equivalents | $90.85M | $29.84M | n/a | $70.52M |
| Total assets | $461.54M | $418.77M | $1.04B | $190.07M |
| Total liabilities | $119.80M | $123.04M | $245.04M | $46.37M |
| Shareholders' equity | $341.74M | $295.73M | $796.33M | $143.70M |
| Return on year-end equity | -19.5% | -36.2% | -5.5% | 13.6% |
| Shares outstanding | 128.55M | 46.74M | 127.69M | 36.32M |
Revenue, most recent five fiscal years
| Fiscal year | Cytek Biosciences, Inc. | Quanterix Corp | 10x Genomics, Inc. | 908 Devices Inc. |
|---|---|---|---|---|
| Latest | $201.49M Ended 2025-12-31 | $138.90M Ended 2025-12-31 | $642.82M Ended 2025-12-31 | $56.20M Ended 2025-12-31 |
| 1 year earlier | $200.45M Ended 2024-12-31 | $137.42M Ended 2024-12-31 | $610.78M Ended 2024-12-31 | $47.75M Ended 2024-12-31 |
| 2 years earlier | $193.01M Ended 2023-12-31 | $122.37M Ended 2023-12-31 | $618.73M Ended 2023-12-31 | $50.23M Ended 2023-12-31 |
| 3 years earlier | $164.04M Ended 2022-12-31 | $105.52M Ended 2022-12-31 | $516.41M Ended 2022-12-31 | $46.85M Ended 2022-12-31 |
| 4 years earlier | $127.95M Ended 2021-12-31 | $110.56M Ended 2021-12-31 | $490.49M Ended 2021-12-31 | $42.21M Ended 2021-12-31 |